


Asprius Lifesciences develops new drug to treat Diabetic Neuropathy, files patent

by **Rashtra Times** in Business Reading Time: 2 mins read 👍 0 👎 0 AA 💬 0



Vishal Zinzuwadia, Chairman & MD - Asprius Lifesciences

Ahmadabad. One of India's fastest growing homegrown research-oriented pharmaceutical companies, Gujarat-based Asprius Lifesciences, has achieved a milestone in the treatment of Diabetic Neuropathy, a condition that causes nerve damage in peripheral areas of the body, leading to symptoms like weakness, numbness and acute pain in hands and feet. With astute focus on evidence-based medicines, extensive research and scientific formulations, Asprius Lifesciences has come up with a Fixed-Dose Combination (FDC) that is expected to treat peripheral neuropathy, a common condition with which over 2% of the global population deals currently.



Buy Now Antivirus

Huge Discounts Available. Up to ₹4,199 Off on McAfee's Antivirus. Limited Period Offer.

McAfee

Open >






While confirming that a patent for the FDC has already been filed, Vishal Zinzuwadia, Chairman & MD – Asprius Lifesciences, said, “Working on an innovation-based proposition, we have relentlessly been developing several groundbreaking pharmaceutical products in our bid to empower the medical fraternity and enhance patient treatment, especially when conventional therapies are ineffective. By actively addressing medical conditions that increase the risk of developing neuropathy and introducing neuro-protective medications, the company aims to support early neuronal regeneration and minimize the impact of the condition.”

The FDC development is spearheaded by the company's medical director and renowned inventor Dr Sanjay Agrawal, who holds patents for nearly 42 other formulations. Elaborating on the need of immediately addressing the Diabetic Neuropathy scenario in the country, Dr Agrawal pointed that “India has a high prevalence of diabetes, with an estimated 77 million adults living with the disease, projected to rise to 101.2 million by 2030. In fact type 2 diabetes accounts for about 90-95% of all cases in India, and is often associated with lifestyle factors such as poor diet, sedentary lifestyle, and obesity. It is high time we addressed this prevalent condition, especially as Diabetic Neuropathy can damage specific subdivision of the nervous system.”

The Asprius Lifesciences Ahmadabad-based company is going to apply few more patents shortly.

Tags: [Ahmadabad](#) [Asprius Lifesciences](#) [Dr Sanjay Agrawal](#) [Vishal Zinzuwadia](#)

Stay Connected test

 123 Followers	 33k Followers	 110k Subscribers	 23.8k Followers
 99 Subscribers			



#1 Share Market Trading Course

ASTA



Trending

Comments

Latest

Gujarat's famous "Patola by Nirmal Salvi" inaugurates his showroom in Mumbai

MARCH 8, 2022



The Party & Travel Group (PARTRA) hosted its first grand event of the year in Mumbai

FEBRUARY 4, 2021



Soft Launch of CSR 762 by Svitch Bike!

NOVEMBER 22, 2021



Chalo Introduce India's first UV(Ultraviolet) sanitize cab service

JUNE 3, 2021

Recent News